NCT04628585 - Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

January 31, 2038

Study Completion Date

January 31, 2038

Conditions

Sickle Cell Disease

Interventions

OTHER

Safety and efficacy assessments

Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant

Trial Locations (16)

Columbia University Medical Center, New York

Cohen Children's Medical Center, New Hyde Park

Children's Hospital of Philadelphia, Philadelphia

Warren Grant Magnuson Clinical Center, Bethesda

Virginia Commonwealth University, Richmond

The University of North Carolina, Chapel Hill

Duke University Medical Center, Durham

Medical University of South Carolina, Charleston

Children's Healthcare of Atlanta, Atlanta

University of Alabama, Birmingham

University of Minnesota Masonic Children's Hospital, Minneapolis

Hospital Necker, Paris

Baylor College of Medicine, Houston

UCSF Benioff Children's Hospital Oakland, Oakland

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Hackensack University Medical Center, Hackensack